Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D008875:Middle Aged
D015255:Idarubicin; D003630:Daunorubicin